[1] http://www.alz.org/dementia/vascular-dementia-symptoms.asp
[2] Pavlovic, A., Pavlovic, D., Aleksic, V. and Sternic, N. (2013) Vascular Dementia: Facts and Controversies. Srp Arch CelokLek, 141, 247-255.
[3] Hebert, R. and Brayne, C. (1995) Epidemiology of Vascular Dementia. Neuroepidemiology, 14, 240.
http://dx.doi.org/10.1159/000109800
[4] Wright, C.B. (2015) Etiology, Clinical Manifestations and Diagnosis of Vascular Dementia (on Line). www.uptodate.com/contents/etiology-clinical-manifestations-anddiagnosis-of-vasculardementia?Source=search_result&search+vascular+dementia&selected Title = 1~44
[5] Gorelick, P.B., Scuteri, A., Black, S.E., Decarli, C., Greenberg, S.M., Iadecola, C., et al. (2011) Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke, 42, 2672-2713.
http://dx.doi.org/10.1161/STR.0b013e3182299496
[6] Benisty, S. (2013) Current Concepts in Vascular Dementia. Geriatr Psychol Neuropsychiatr Vieil, 11, 171-180.
[7] Hachinski, V., Iadecola, C., Petersen, R.C., Breteler, M.M., Nyenhuis, D.L., Black, S.E., et al. (2006) National Institute of Neurological Disorders and Stroke—Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards. Stroke, 37, 2220-2241.
http://dx.doi.org/10.1161/01.STR.0000237236.88823.47
[8] Caplan, L.R. (1995) Binswanger’s Disease—Revisited. Neurology, 45, 626-633.
http://dx.doi.org/10.1212/WNL.45.4.626
[9] Olszewski, J. (1962) Subcortical Arteriosclerotic Encephalopathy. Review of the Literature on the So-Called Binswanger’s Disease and Presentation of Two Cases. World Neurology, 3, 359-375.
[10] Malemud, C.J. (2006) Matrix Metalloproteinases (MMPs) in Health and Disease: An Overview. Frontiers in Bioscience, 11, 1696-1701. (Review).
[11] Mroczko, B., Groblewska, M. and Barcikowska, M. (2013) The Role of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in the Pathophysiology of Neurodegeneration: A Literature Study. Journal of Alzheimer’s Disease, 37, 273-283.
[12] Rosenberg, G.A., Navratil, M., Barone, F. and Feuerstein, G. (1996) Proteolytic Cascade Enzymes Increase in Focal Cerebral Ischemia in Rat. Journal of Cerebral Blood Flow & Metabolism, 55, 300-309
[13] Stomrud, E., Björkqvist, M., Janciauskiene, S., Minthon, L. and Hansson, O. (2010) Alterations of Matrix Metalloproteinases in the Healthy Elderly with Increased Risk of Prodromal Alzheimer’s Disease. Alzheimer’s Research & Therapy, 2, 20.
http://dx.doi.org/10.1186/alzrt44
[14] Helbecque, N., Cottel, D., Hermant, X. and Amouyel, P. (2007) Impact of the Matrix Metalloproteinase MMP-3 on Dementia. Neurobiology of Aging, 28, 1215-1220.
http://dx.doi.org/10.1016/j.neurobiolaging.2006.05.030
[15] Saarela, M.S., Lehtimäki, T., Rinne, J.O., Hervonen, A., Jylhä, M., Röyttä, M., et al. (2004) Interaction between Matrix Metalloproteinase 3 and the Epsilon 4 Allele of Apolipoprotein E Increases the Risk of Alzheimer’s Disease in Finns. Neuroscience Letters, 367, 336-339.
http://dx.doi.org/10.1016/j.neulet.2004.06.027
[16] Maeda, A. and Sobel, R.A. (1996) Matrix Metalloproteinases in the Normal Human Central Nervous System, Microglial Nodules, and Multiple Sclerosis Lesions. Journal of Neuropathology and Experimental Neurology, 55, 300-309.
http://dx.doi.org/10.1097/00005072-199603000-00005
[17] Clark, A.W., Krekoski, C.A., Bou, S.S., Chapman, K.R. and Edwards, D.R. (1997) Increased Gelatinase A (MMP-2) and Gelatinase B (MMP-9) Activities in Human Brain after Focal Ischemia. Neuroscience Letters, 238, 53-56.
http://dx.doi.org/10.1016/S0304-3940(97)00859-8
[18] Anthony, D.C., Ferguson, B., Matyzak, M.K., Miller, K.M., Esiri, M.M. and Perry, V.H. (1997) Differential Matrix Metalloproteinase Expression in Cases of Multiple Sclerosis and Stroke. Neuropathology and Applied Neurobiology, 23, 406-415.
http://dx.doi.org/10.1111/j.1365-2990.1997.tb01315.x
[19] Rosenberg, G.A., Sullivan, N. and Esiri, M.M. (2001) White Matter Damage Is Associated with Matrix Metalloproteinases in Vascular Dementia. Stroke, 32, 1162-1168.
http://dx.doi.org/10.1161/01.STR.32.5.1162
[20] Roman, G.C., Tatemichi, T.K., Erkinjuntti, T., Cummings, J.L., Masdeu, J.C., Garcia, J.H., Amaducci, L., Orgogozo, J.M., Brun, A., Hofman, A., et al. (1993) Vascular Dementia: Diagnostic Criteria for Research Studies. Report of the NINDS-AIREN International Workshop. Neurology, 43, 250-260.
http://dx.doi.org/10.1212/WNL.43.2.250
[21] Boster Biological Technology Co., Ltd. (2014)
http://www.bosterbio.com/human-timp-1-picokine-elisa-kitek0520.html
[22] Boster Biological Technology Co., Ltd. (2014)
http://www.bosterbio.com/human-mmp-3-picokine-elisa-kitek0461.html
[23] Chakraborti, S., Mandal, M., Das, S., Mandal, A. and Chakraborti, T. (2003) Regulation of Matrix Metalloproteinases: An Overview. Molecular and Cellular Biochemistry, 253, 269-285.
http://dx.doi.org/10.1023/A:1026028303196
[24] Rosenberg, G.A., Cunningham, L.A., Wallace, J., Alexander, S., Estrada, E.Y., Grossetete, M., et al. (2001) Immunohistochemistry of Matrix Metalloproteinases in Reperfusion Injury to Rat Brain: Activation of MMP-9 Linked to Stromelysin-1 and Microglia in Cell Cultures. Brain Research, 893, 104-112.
http://dx.doi.org/10.1016/S0006-8993(00)03294-7
[25] Lorenzl, S., Buerger, K., Hampel, H. and Beal, M.F. (2008) Profiles of Matrix Metalloproteinases and Their Inhibitors in Plasma of Patients with Dementia. International Psychogeriatrics, 20, 67-76.
http://dx.doi.org/10.1017/s1041610207005790
[26] Stetler-Stevenson, W.G. (2008) The Tumor Microenvironment: Regulation by MMP-Independent Effects of Tissue Inhibitor of Metalloproteinases-2. Cancer and Metastasis Reviews, 27, 57-66.
http://dx.doi.org/10.1007/s10555-007-9105-8
[27] Lovelock, J.D., Baker, A.H., Gao, F., Dong, J.F., Bergeron, A.L., McPheat, W., et al. (2005) Heterogeneous Effects of Tissue Inhibitors of Matrix Metalloproteinases on Cardiac Fibroblasts. AJP: Heart and Circulatory Physiology, 288, H461-H468.
http://dx.doi.org/10.1152/ajpheart.00402.2004
[28] Roycik, M.D., Myers, J.S., Newcomer, R.G. and Sang, Q.X. (2013) Matrix Metalloproteinase Inhibition in Atherosclerosis and Stroke. Current Molecular Medicine, 13, 1299-1313.
http://dx.doi.org/10.2174/15665240113139990067